Last updated on July 2019

A Study of KZR-616 in Patients With Systemic Lupus Erythematosus With and Without Nephritis


Brief description of study

This is a Phase 1b/2, multi-center study in which patients will receive KZR-616, administered as a subcutaneous (SC) injection weekly for 13 weeks.

The study consists of 2 parts. Part 1, the Phase 1b, is an open-label multiple dose escalation study to evaluate the safety and tolerability of KZR-616 in patients with systemic lupus erythematosus (SLE) with and without nephritis. Part 2, the Phase 2, is a randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of KZR-616 in patients with active proliferative lupus nephritis (LN).

Clinical Study Identifier: NCT03393013

Find a site near you

Start Over

KZR Research Site

Parkville, Australia
3.22miles
  Connect »